BCL-2 Inhibitor Compounds with Improved Solubility and Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BCL-2 inhibitors, such as ABT-737 and ABT-263, face challenges with low aqueous solubility and bioavailability, leading to dose-limiting toxicities and reduced therapeutic efficacy.
Innovation Solution
Development of novel compounds, represented by structural formulas (A), (A-1), (A-2), (A-3), (A-4), (A-5), (AA), (AA-1), (AA-2), (AA-3), (AA-4), and (AA-5), which inhibit BCL-2 family proteins with improved pharmaceutical solubility, stability, bioavailability, and therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BCL-2 inhibitors (ABT-737, ABT-263) are used to achieve BCL-2 inhibition, then therapeutic efficacy is improved, but aqueous solubility and bioavailability deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically modifying the chemical structure of BCL-2 inhibitor compounds. Specifically, the invention varies substituents at different positions (R1-R12 groups) to alter physicochemical properties while maintaining BCL-2 binding affinity. This includes changing molecular weight, lipophilicity, and hydrogen bonding capabilities to improve aqueous solubility without sacrificing therapeutic efficacy against BCL-2 dependent tumors.
2Reliability
If current BCL-2 inhibitors (ABT-737, ABT-263) are used to achieve BCL-2 inhibition, then therapeutic efficacy is improved, but bioavailability deteriorates
Solution Approach 1:
The patent modifies bioavailability through parameter changes in molecular structure. The invention optimizes oral bioavailability by adjusting key parameters including molecular weight (keeping within acceptable ranges), lipophilicity (balancing LogP values), and metabolic stability. These structural modifications enable improved absorption and pharmacokinetic properties while preserving the ability to inhibit BCL-2 and achieve therapeutic effects in BCL-2 dependent malignancies.
3Reliability
If current BCL-2 inhibitors are used to achieve tumor cell killing, then therapeutic efficacy is improved, but dose-limiting toxicities occur
Solution Approach 1:
The patent applies local quality by designing compounds with selective action. The invention creates BCL-2 inhibitors that preferentially target and accumulate in tumor cells expressing high levels of BCL-2, while sparing normal cells. This selectivity is achieved through structural features that enhance binding affinity for overexpressed BCL-2 in malignancies while reducing off-target effects, thereby improving the therapeutic index and reducing dose-limiting toxicities such as thrombocytopenia.
Solution Approach 2:
The patent employs partial action by designing inhibitors with optimized potency levels. Rather than maximizing inhibition at all costs, the invention creates compounds that achieve sufficient BCL-2 inhibition to kill tumor cells while maintaining a safety margin that prevents severe toxicities. This balanced approach allows effective tumor cell killing at doses below the threshold for dose-limiting adverse events.
4Reliability
If current BCL-2 inhibitors are used to achieve apoptosis induction, then therapeutic efficacy is improved, but pharmaceutical stability deteriorates
Solution Approach 1:
The patent addresses pharmaceutical stability through parameter changes in molecular structure. The invention modifies chemical groups and bonding patterns to enhance metabolic stability and resistance to degradation. Specific structural features are incorporated to prevent premature metabolism by cytochrome P450 enzymes and other metabolic pathways, thereby improving pharmaceutical stability while preserving the ability to induce apoptosis in BCL-2 dependent tumor cells.
Data Source
AI summary
The disclosure includes compounds of Formula (A), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.